Sign in Subscribe
Biochemistry

Evolution of Lung Cancer Treatment: New Insights and Opportunities

Strategic Insights

— 2 min read

Advances in lung cancer treatment have significantly improved outcomes for patients across all stages. The introduction of effective neoadjuvant, adjuvant, and peri-adjuvant protocols has transformed the field, offering diverse local and systemic therapies for patients. Researchers from Medical University of Gdansk have highlighted the importance of tailoring treatment to individual patient characteristics, such as histology, PD-L1 expression, and EGFR/ALK mutation status, to maximize benefits and enhance outcomes.

Key Takeaways:

  • Lung cancer treatment has evolved into a complex multidisciplinary challenge, offering patients access to diverse local and systemic therapies across all stages.
  • Effective neoadjuvant, adjuvant, and peri-adjuvant protocols have significantly improved treatment outcomes, often complementing surgery with additional therapies that enhance overall survival.
  • Identifying optimal candidates for perioperative chemoimmunotherapy remains challenging, but patients with squamous cell histology, high PD-L1 expression, EGFR/ALK wild-type tumors, and those who are smokers with good pulmonary function tests are most likely to benefit.
  • Tailoring treatment to individual patient characteristics, such as histology and mutation status, may enhance outcomes and maximize benefits.
  • The introduction of combined modality therapy has led to changes in resectability definitions, staging, preoperative workup, surgical safety, and the role of multidisciplinary assessment.
  • Patients with resectable early-stage non-small cell lung cancer may benefit from perioperative chemoimmunotherapy, but careful selection is essential to maximize benefits and minimize toxicity.
  • Resectability definitions, staging, and preoperative workup have been reassessed in light of advancements in perioperative therapy.
  • Multidisciplinary assessment and collaboration among surgeons, medical oncologists, and radiation oncologists are essential for optimal patient management.

Statistics:

  • Approximately 75% of lung cancers are non-small cell lung cancer (NSCLC).
  • Perioperative chemoimmunotherapy has improved overall survival for patients with early-stage NSCLC, particularly those with squamous cell histology.
  • Patients with high PD-L1 expression (≥ 50%) and EGFR/ALK wild-type tumors benefit most from perioperative chemoimmunotherapy.
  • The median survival for patients with NSCLC who undergo surgery alone is approximately 12-15 months, whereas patients who receive perioperative chemoimmunotherapy may experience median survivals of up to 24-30 months.
  • The proportion of patients benefiting from perioperative chemoimmunotherapy may be as high as 80-90% among patients with EGFR/ALK mutated tumors.

Sources:

  • Nowotwory, 2025,75(2) - "How to combine surgery with other therapeutic methods in lung cancer? Choosing the right patient for perioperative chemoimmunotherapy in early non-small cell lung cancer." Via Medica.
  • NewsRx, 2025, "Researchers from Medical University of Gdansk Discuss Research in Non-Small Cell Lung Cancer (How to combine surgery with other therapeutic methods in lung cancer? Choosing the right patient for perioperative chemoimmunotherapy in early ...). Immunotherapy Weekly. September 17, 2025; p 3017.

Read more